Dăbâca (RO)
{name}
{subtitle}
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~21 mi. (Cluj-Napoca, Romania, +158 more cities)
facility
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2506)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~21 mi. (Cluj-Napoca, Romania, +137 more cities)
facility
Spitalul Universitar CF Cluj-Napoca ( Site 1103), +1 more facility
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
city
~21 mi. (Cluj-Napoca, Romania, +126 more cities)
facility
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), +1 more facility
condition
Adenocarcinoma of the Gastroesophageal Junction, +1 more condition
drug
FOLFOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~21 mi. (Cluj-Napoca, Romania, +92 more cities)
facility
S.C. Radiotherapy Center Cluj S.R.L ( Site 0252)
condition
Bladder Urothelial Carcinoma
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~21 mi. (Cluj-Napoca, Romania, +105 more cities)
facility
Medisprof ( Site 1107)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib
drug type
targeted therapy
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~21 mi. (Cluj-Napoca, Romania, +115 more cities)
facility
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1101)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type